validated reverse phase hplc method for the determination of dehp content in reconstituting diluents and in reconstituted solutions of imipenem and cilastatin for injection
Clicks: 210
ID: 247194
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
210 views
45 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #68 of 235 articles by views in Journal of pharmaceutical and biomedical analysis
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 235 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A simple, rapid, accurate and economic reverse phase HPLC method was developed and validated for determination of di-(2-ethylhexyl)phthalate (DEHP) in reconstituting diluents and reconstituted solutions of imipenem and cilastatin for injection The method was applied to detect any leaching enhancement in presence of imipenem and cilastatin in reconstituted injections. Imipenem and cilastatin for injection is a widely used broad spectrum beta-lactam antibiotic. As per requirements of various regulatory authorities of different countries, DEHP content needs to be monitored in the reconstituting diluents used to reconstitute injections. The proposed method is a unique method wherein DEHP can be determined directly without any sample pre-treatment before analysis. The method can be used as a good quality control tool to control the leaching of DEHP in the reconstituting diluents and reconstituted injections. The method utilizes C18 column (250 × 4.6 mm, 5μ) and a mixture of methanol, propan-2-ol and water as mobile phase. DEHP was detected at 225 nm. The method has low limit of quantification (0.058 μg mL-1) which is much below the acceptance limit calculated as per USFDA tolerance criteria (3.5 μg mL-1 for adults and 0.3 μg mL-1 for neonates and infants).
| Reference Key |
chaudhary2010e-journalvalidated
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;A. K. Chaudhary;S. Ankushrao Waske;S. Yadav;T. G. Chandrashekhar;Vandana Singh |
| Journal | Journal of pharmaceutical and biomedical analysis |
| Year | 2010 |
| DOI |
10.1155/2010/805248
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.